Skip to main content
Clinical Trials/NCT03511066
NCT03511066
Terminated
Phase 2

A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects With Acute Uncomplicated Influenza A Infection

Celltrion1 site in 1 country228 target enrollmentDecember 9, 2016

Overview

Phase
Phase 2
Intervention
CT-P27 90 mg/kg
Conditions
Influenza A
Sponsor
Celltrion
Enrollment
228
Locations
1
Primary Endpoint
Time to Resolution of Influenza Symptoms and Fever
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

This study is a Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled study evaluating the efficacy and safety of CT-P27 in subjects with acute uncomplicated influenza A infection.

Detailed Description

This study is a Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled study. All enrolled subjects will be given a single dose of 90 mg/kg CT-P27, 45 mg/kg CT-P27, or placebo intravenously over 90 minutes (±15 minutes) on Day 1 and then followed by Day 110.

Registry
clinicaltrials.gov
Start Date
December 9, 2016
End Date
June 15, 2018
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Celltrion
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or Female subjects between the ages of 19 and 64 years, both inclusive
  • Diagnosed with influenza A at screening using rapid influenza diagnostic test
  • Onset of influenza symptoms and fever is within 48 hours at screening
  • At least 2 of symptoms (moderate to severe in intensity)
  • ≥38.0'C body temperature at screening

Exclusion Criteria

  • Taking antiviral treatment for influenza or has a history of using these antivirals within 14 days prior to the administration of study drug
  • Positive influenza B or A+B infection

Arms & Interventions

CT-P27 90 mg/kg

CT-P27 will be administrated once in IV infusion.

Intervention: CT-P27 90 mg/kg

CT-P27 45mg/kg

CT-P27 will be administrated once in IV infusion.

Intervention: CT-P27 45 mg/kg

Placebo

Placebo will be administrated once in IV infusion.

Intervention: Placebo

Outcomes

Primary Outcomes

Time to Resolution of Influenza Symptoms and Fever

Time Frame: Twice a day (Morning and Evening) from Day 1 to Day 8

Time to resolution of influenza symptoms (cough, sore throat, nasal congestion, headache, feeling feverish, body aches and pains, and fatigue) and fever (\<37.8)

Study Sites (1)

Loading locations...

Similar Trials